ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will unveil ...

ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ...

Treatment with darovasertib resulted in robust ocular tumor shrinkage, lower simulated radiation doses to the eye and ...

CrowdStrike bets on agentic AI with new Falcon data layer and security operations center agents - SiliconANGLE ...

ENDO 2025 featured the latest research on novel therapies for adrenal and neuroendocrine conditions, new data on various ...

Instil Bio (TIL) announced that ImmuneOnco Biopharmaceuticals presented preliminary efficacy and safety data of ‘2510 as monotherapy in a Phase 1 ...

Sun Communities ( ($SUI) ) has issued an announcement. Sun Communities, Inc. released an investor presentation on September 3, 2025, highlighting ...

PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients ...

These data were presented at the International Congress of Inborn Errors of Metabolism 2025 (ICIEM2025) in Kyoto, Japan, on September 4, 2025, in a poster presentation (Poster Ref: P-662). These data ...

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with ...

First disclosure of global interim phase 2 data for BioNTech & Bristol Myers Squibb PD-L1xVEGF-A bispecific antibody pumitamig in patients with ES-SCLC shows encouraging antitumor activity ...